Why FDA Leadership Shifts Matter to Fertility Patients

If you're mid-cycle right now, the last thing on your mind is who runs the FDA. You're counting follicles, watching the clock on your trigger shot, refreshing your patient portal. Federal agency politics feel a thousand miles away from the kitchen counter where your meds are lined up.

They aren't.

The planned exit of FDA Commissioner Marty Makary has set off a quiet alarm among reproductive health advocates, mostly because of what it could mean for access to mifepristone and other abortion-related medications.¹ That's the headline. But the same agency, the same approval pathways, and the same political pressure points govern almost every drug you inject, swallow, or apply during fertility treatment. When the leadership of that agency becomes a battleground, the fertility community has a stake in the outcome too — even when nobody is talking about us.

Here's a clear-eyed look at why.

What the FDA actually does for your treatment

Almost every medication in a standard IVF or IUI protocol is FDA-regulated. Gonadotropins for ovarian stimulation. GnRH agonists and antagonists to control ovulation timing. hCG and leuprolide as trigger shots. Progesterone in oil, suppositories, and gels for luteal support. Estrogen patches and pills for frozen transfer prep. None of these are niche compounds — they're approved drugs with labels, manufacturing oversight, and supply chains the FDA signs off on.

The agency also decides:

• Whether a drug stays on the market or gets pulled
• How it can be prescribed, dispensed, and shipped (including by mail and by compounding pharmacies)
• Which manufacturers can produce generics
• How shortages are managed when supply gets tight

When any of those levers move, your clinic feels it. You feel it at the pharmacy counter.

Why a leadership transition matters more than it sounds

FDA commissioners don't personally approve your Menopur. But they set the agency's posture — how aggressive it is about enforcement, how it responds to political pressure from Congress and the White House, and how it handles petitions from advocacy groups asking it to restrict or expand access to specific drugs.

Reporting on Makary's exit notes that anti-abortion organizations have been preparing to push the FDA to roll back access to mifepristone, and that a leadership vacancy creates an opening to install someone more receptive to those petitions.¹ The mechanism they'd use — reopening a drug's safety review, tightening prescribing rules, restricting mail-order dispensing — is the same mechanism that could, in theory, be applied to any drug with political enemies.

Fertility medications haven't been a target in the same way. But two adjacent pressures are worth watching:

Compounded medications. Many fertility patients rely on compounded progesterone, estradiol, and other hormones, especially when commercial versions are short or unaffordable. The FDA has wide discretion over what compounding pharmacies can produce and ship across state lines. A more restrictive posture there would hit fertility patients first and hardest.

Embryo and IVF politics. After the 2024 Alabama Supreme Court ruling that frozen embryos are children under state law, IVF became explicitly political in a way it hadn't been before. Federal agencies, including the FDA, regulate adjacent areas — tissue handling, lab standards, certain ART-related products. An agency leadership that views embryos through a personhood lens could, over time, reshape rules that clinics currently operate under.

None of this is imminent. None of it is guaranteed. But "unlikely" is not the same as "impossible," and the fertility community learned in 2022 and again in 2024 that legal and regulatory ground can shift faster than anyone predicted.

What this is not

This isn't a reason to panic-order a year of meds or assume your next cycle is in jeopardy. Your protocol next month will look like your protocol this month. Clinics aren't changing practice based on a commissioner transition.

It's also not a partisan argument. Fertility patients exist across every political identity, and the question of who runs the FDA matters regardless of which party is in the White House. The point is narrower: an agency that touches every part of your treatment is going through a transition, and the people lobbying hardest about that transition are not thinking about you.

That last part is the one worth sitting with.

Where the infertility community actually has a voice

The most established advocacy channel for fertility patients in the U.S. is RESOLVE: The National Infertility Association, which runs an annual federal advocacy push and recently launched a month-long action campaign asking patients and allies to contact lawmakers about family-building access.² Their Advocacy Day brings patients to Capitol Hill to talk directly to congressional offices about IVF coverage, military and veteran family-building benefits, and protections for assisted reproduction.

The practical version of "making your voice heard" usually looks like:

• Signing onto action alerts when bills affecting IVF or ART move in Congress or your state legislature
• Writing a short, personal note to your representatives — patient stories move offices more than statistics do
• Submitting public comments when the FDA opens a docket on a relevant rule (these are read and counted)
• Supporting professional organizations like ASRM that file formal comments on regulatory proposals

None of this requires becoming an activist. A ten-minute email from someone who's been through three retrievals carries weight that a polished lobbyist's letter doesn't.

What to ask, and what to watch

If you want to stay oriented without drowning in news:

• Ask your clinic which of your medications are commercially manufactured versus compounded, and whether they have a backup source if supply tightens. Clinics track this; most will tell you plainly.
• Ask your pharmacy whether they ship across state lines and what their contingency is if mail-order rules change.
• Watch for FDA dockets or rule changes affecting compounding pharmacies, REMS programs (the restricted distribution programs some drugs operate under), and ART-adjacent tissue regulations.
• Bookmark one advocacy organization whose alerts you trust, and actually open the emails.

The reframe

It is exhausting to be told that one more thing — on top of the injections, the bills, the waiting — also requires your political attention. You did not sign up to be a policy expert. You signed up to have a baby.

But here is the quiet truth of the last few years: the people who decide what your treatment looks like are increasingly not your doctor. They're regulators, legislators, and judges, most of whom have never sat in a monitoring room at 7am. The fertility community is large — one in six adults globally experiences infertility — and it has historically been quiet, partly because the grief is private and partly because the stigma is real.

Leadership transitions at agencies like the FDA are a reminder that quiet is a choice with consequences. You don't have to be loud. You just have to be counted.

¹: Reporting on FDA Commissioner Marty Makary's planned exit and concerns from reproductive health advocates about regulatory pressure on mifepristone access. ²: RESOLVE: The National Infertility Association announcement of its inaugural Month of Action in May 2026, including federal advocacy and Capitol Hill engagement.